Related Experiment Video
Updated: May 19, 2026
11:35
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
Associations between TNFAIP3 gene polymorphisms and systemic lupus erythematosus: a meta-analysis
1Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Korea University Medical Center, Seoul, Korea. lyhcgh@korea.ac.kr
Genetic Testing and Molecular Biomarkers
|August 29, 2012
Summary
Tumor necrosis factor-alpha-inducible protein 3 (TNFAIP3) gene variations increase systemic lupus erythematosus (SLE) risk in Asian and European populations. This meta-analysis confirms TNFAIP3 polymorphisms as a significant factor in SLE susceptibility across diverse ethnic groups.
Area of Science:
- Genetics and Immunology
- Autoimmune Diseases Research
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a significant genetic component.
- The role of specific genetic polymorphisms, such as those in the tumor necrosis factor-alpha-inducible protein 3 (TNFAIP3) gene, in SLE susceptibility requires further investigation across diverse populations.
Purpose of the Study:
- To investigate the association between tumor necrosis factor-alpha-inducible protein 3 (TNFAIP3) polymorphisms and susceptibility to systemic lupus erythematosus (SLE).
- To evaluate this association across different ethnic groups through a comprehensive meta-analysis.
Main Methods:
- A meta-analysis was performed on eight comparative studies examining the association between TNFAIP3 polymorphisms and SLE susceptibility.
- Studies included Asian, European, and African American populations.
- Fixed and random effects models were utilized to analyze the data.
Main Results:
- The minor allele of the rs2230926 polymorphism was significantly associated with increased SLE risk in the overall cohort, as well as in Asian and European populations.
- The rs5029939 polymorphism also showed a significant association with SLE risk in the overall cohort and specifically in Europeans.
- The rs3757173 polymorphism was associated with SLE risk in the overall cohort, while rs6922466 showed no significant association.
Conclusions:
- TNFAIP3 gene polymorphisms are confirmed to be associated with systemic lupus erythematosus susceptibility.
- The findings highlight a significant role for TNFAIP3 variants, particularly rs2230926 and rs5029939, in conferring SLE risk among Asian and European populations.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...